Poorly Differentiated Esophageal Neuroendocrine Carcinoma Treated With the CDK4/6 Inhibitor, Palbociclib: A Case Report and Literature Review

Am J Ther. 2018 Sep/Oct;25(5):e595-e598. doi: 10.1097/MJT.0000000000000610.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Review

MeSH terms

  • Aged
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Neuroendocrine / diagnostic imaging
  • Carcinoma, Neuroendocrine / drug therapy*
  • Carcinoma, Neuroendocrine / pathology
  • Carcinoma, Neuroendocrine / secondary
  • Cyclin-Dependent Kinase 4 / antagonists & inhibitors
  • Cyclin-Dependent Kinase 6 / antagonists & inhibitors
  • Esophageal Neoplasms / diagnostic imaging
  • Esophageal Neoplasms / drug therapy*
  • Esophageal Neoplasms / pathology
  • Esophagus / diagnostic imaging
  • Esophagus / pathology
  • Humans
  • Liver / diagnostic imaging
  • Liver / pathology
  • Liver Neoplasms / diagnostic imaging
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / pathology
  • Liver Neoplasms / secondary
  • Lymphatic Metastasis / diagnostic imaging
  • Magnetic Resonance Imaging
  • Male
  • Piperazines / pharmacology
  • Piperazines / therapeutic use*
  • Pyridines / pharmacology
  • Pyridines / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Piperazines
  • Pyridines
  • CDK4 protein, human
  • CDK6 protein, human
  • Cyclin-Dependent Kinase 4
  • Cyclin-Dependent Kinase 6
  • palbociclib